Regenxbio

REGENXBIO is a clinical-stage biotechnology company focused on improving lives through the curative potential of gene therapy. It uses its NAV Technology Platform, which includes AAV vectors such as AAV8 and AAV9, to develop in-house candidates and to license the platform to third parties. Its pipeline includes RGX-121 for MPS II, RGX-202 for Duchenne muscular dystrophy, and ABBV-RGX-314 for retinal diseases, which it is developing with AbbVie.